Skip to main content
. 2018 Apr 20;9(30):21495–21511. doi: 10.18632/oncotarget.25138

Figure 7. Differential therapeutic response of Ln229 cells stably expressing split-Renilla luciferase complementation biosensor with different p53 mutants (p53wt, p53Y220C, p53G245S, p53R282W) to chemotherapy (TMZ) in the presence of different doses of PhiKan083, as assessed by FACS analysis for the induced apoptotic population.

Figure 7

Graph showing the quantitative results of parental Ln229 cells (A) and, Ln229 variant cells stably expressing different p53 biosensors: Ln229-NRluc-p53wt-CRluc (B), Ln229-NRluc-p53Y220C-CRluc (C), Ln229-NRluc-p53G245S-CRluc (D), Ln229-NRluc-p53R282W-CRluc (E), tested in response to the different treatment doses of PhiKan083 (0, 12.5, 25 and 50 μM) or Tezmozolomide (0, 50 and 100 μM), and as a combination.